Vitality Watch

Dossier rss preclinical 06-oct-2026
Animal model, organoid, or cell-culture result — not yet human

Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan

Key claim: Novel flavonoid senotherapeutics identified by phenotypic drug discovery reduce cellular senescence and improve multiple markers of healthspan.

Abstract

Aging Cell, Volume 25, Issue 10, October 2026.

Why this matters

Phenotypic (as opposed to target-based) drug discovery is one of the few routes that has reliably produced senotherapeutics, and flavonoids already dominate the clinical senolytic pipeline through quercetin and fisetin. Adding more flavonoid hits widens the chemical space the field can draw on but does not change the central translation gap: preclinical multi-marker healthspan gains from this chemotype have so far only partially transferred to human endpoints.

Source

Link

Briefing card

Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
Stage: preclinical · rss · 06-oct-2026

If you are tracking fisetin as a senolytic, this preclinical screen suggests the compounds likely to reach future trials may be fisetin-derived analogs rather than fisetin itself.

Novel flavonoid senotherapeutics identified by phenotypic drug discovery reduce cellular senescence and improve multiple markers of healthspan.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70736?af=R

build build 880 · 2bcef25 · 2026-11-18